<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045719</url>
  </required_header>
  <id_info>
    <org_study_id>ABC2013</org_study_id>
    <nct_id>NCT02045719</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors</brief_title>
  <acronym>cat´sclaw</acronym>
  <official_title>Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Medicina do ABC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Medicina do ABC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and
      antitumor properties. Patients and methods: This prospective phase II study will assess the
      effects of a 100-mg dose of a dry extract of U. tomentosa three times per day on individuals
      with advanced solid tumors, with no further therapeutic options and with at least 2 months
      life expectancy. In addition, several biochemical and inflammatory parameters will be
      analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of benefits on quality of life after treatment during two months</measure>
    <time_frame>two months</time_frame>
    <description>Assess the efficacy and safety of a dry extract of U. tomentosa on individuals who had solid tumors with no further therapeutic options</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>cat's claw</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg dose of a dry extract of U. tomentosa three times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>uncaria tomentosa (cat´s claw)</intervention_name>
    <arm_group_label>cat's claw</arm_group_label>
    <other_name>100 mg dose of a dry extract of U. tomentosa three times per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  individuals with advanced solid tumors, with no further therapeutic options and with
             at least 2 moths life expectancy

          -  individuals 18 years of age and older

          -  creatinine levels up to twice the upper limit of normal (ULN)

          -  alanine (ALT) and aspartate (ASP) transaminase levels up to twice the ULN and direct
             bilirubin (DB) levels up to 1.5 times the ULN

          -  in cases with pre-existing liver disease, the ALT, ASP and DB levels could be up to
             2.5 times the ULN

        Exclusion Criteria:

          -  pregnant and breastfeeding women

          -  individuals using chemotherapy or other tumor-targeting antineoplastic treatments,
             except for antalgic radiotherapy

          -  severe kidney or liver failure

          -  known hypersensitiveness to the components of the medication used

          -  past history of emotional disorders that could interfere with the data collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Larissa de Paula</last_name>
    <phone>5511992951626</phone>
    <email>lariclpaula@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisa em Hematologia e Oncologia</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa de Paula</last_name>
      <phone>55992951626</phone>
      <email>lariclpaula@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>January 24, 2014</last_update_submitted>
  <last_update_submitted_qc>January 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Medicina do ABC</investigator_affiliation>
    <investigator_full_name>Felipe Melo Cruz</investigator_full_name>
    <investigator_title>MsC</investigator_title>
  </responsible_party>
  <keyword>cat´s claw</keyword>
  <keyword>uncaria tomentosa</keyword>
  <keyword>quality of life</keyword>
  <keyword>no further therapeutic options</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

